CN1079257C - Powder medicine for treating born and scald - Google Patents
Powder medicine for treating born and scald Download PDFInfo
- Publication number
- CN1079257C CN1079257C CN99112563A CN99112563A CN1079257C CN 1079257 C CN1079257 C CN 1079257C CN 99112563 A CN99112563 A CN 99112563A CN 99112563 A CN99112563 A CN 99112563A CN 1079257 C CN1079257 C CN 1079257C
- Authority
- CN
- China
- Prior art keywords
- weight
- burn
- scald
- portions
- powder medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010053615 Thermal burn Diseases 0.000 title claims abstract description 49
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 239000000843 powder Substances 0.000 title claims description 12
- 239000012528 membrane Substances 0.000 claims abstract description 11
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims abstract description 11
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 10
- 241001116389 Aloe Species 0.000 claims abstract description 10
- 239000004863 Frankincense Substances 0.000 claims abstract description 10
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 229960001763 zinc sulfate Drugs 0.000 claims description 10
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 10
- 241000717739 Boswellia sacra Species 0.000 claims description 9
- 241001057584 Myrrha Species 0.000 claims description 9
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 4
- 244000080767 Areca catechu Species 0.000 claims description 4
- 235000006226 Areca catechu Nutrition 0.000 claims description 4
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 3
- 235000001892 vitamin D2 Nutrition 0.000 claims description 3
- 239000011653 vitamin D2 Substances 0.000 claims description 3
- 231100000241 scar Toxicity 0.000 abstract description 7
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 208000032544 Cicatrix Diseases 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 235000003325 Ilex Nutrition 0.000 abstract 1
- 241000209035 Ilex Species 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 244000173853 Sanguisorba officinalis Species 0.000 abstract 1
- 235000008282 Sanguisorba officinalis Nutrition 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- 241000902900 cellular organisms Species 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 230000037387 scars Effects 0.000 abstract 1
- 235000009529 zinc sulphate Nutrition 0.000 abstract 1
- 239000011686 zinc sulphate Substances 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 25
- 206010052428 Wound Diseases 0.000 description 24
- 238000011282 treatment Methods 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000002674 ointment Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 210000000589 cicatrix Anatomy 0.000 description 5
- 239000003860 topical agent Substances 0.000 description 5
- 238000001804 debridement Methods 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000011241 protective layer Substances 0.000 description 3
- 208000013223 septicemia Diseases 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000003328 fibroblastic effect Effects 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000013935 Electric injury Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- 208000036581 Haemorrhagic anaemia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- -1 alkaline burn Chemical compound 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A powdery medicine of the present invention for treating burns and scalds is prepared from the following raw materials: 1 to 5 portions by weight of egg internal membranes, 5 to 10 portions by weight of biota leaves, 5 to 10 portions by weight of frostbitten malberry leaves, 5 to 10 portions by weight of dahurian angelica roots, 5 to 10 portions by weight of frankincense, 5 to 10 portions by weight of myrrh, 5 to 10 portions by weight of sanguisorba roots, 5 to 10 portions by weight of Chinese ilex leaves, 5 to 10 portions by weight of aloes, 1 to 5 portions by weight of borneol and 0.25 to 0.3 portion by weight of zinc sulphate. The effectiveness ratio of the present invention for treating various burns and scalds is 100%, the curative ratio is 100%, skin grafting does not need to be carried out, and scars can not be left.
Description
The invention belongs to the external used medicine of treatment burn and scald.
At present, the external used medicine of treatment burn is many, and prescription is had nothing in common with each other, and effect is different.As moist expose burn ointment commonly used clinically to small size superficial burns curative effect also can, but undesirable to the deep second degree burn therapeutic effect, third degree burn is invalid substantially, needs by skin-grafting elimination wound surface.At present, general in the world silver sulfadiazine is mainly used in the dry wound surface of burn, the skin-grafting of selecting a good opportunity, no granulation promoting function.
Purpose of the present invention also provides a kind of external used medicine for the treatment of burn, and manufacturing process is simple, and curative effect is reliable, can cure all kinds of burn and scald effectively, and anti-infection ability is strong, and effect is fast, and 30% area need not made skin graft with interior burn and scald.
Powder medicine for treating born and scald of the present invention is to be made by the raw material by following parts by weight:
1～5 part of egg membrane, side uncle leaf 5～10, Folium Mori 5～10, the Radix Angelicae Dahuricae 5～10, Olibanum 5～10, Myrrha 5～10, Radix Sanguisorbae 5～10, Folium Ilicis Purpureae 5～10, Aloe 5～10, Borneolum Syntheticum 1～5, zinc sulfate 0.25～0.3.
In above-mentioned raw materials, also can comprise in the following raw material one or more: catechu 5～10, Herba Centellae 5～10, Mirabilitum crystallina 5～10.
Egg membrane is one deck tunica albuginea in the Ovum crusta Gallus domesticus, and it acts on the cough-relieving record in the Compendium of Material Medica.It contains protein, collagen composition, is used for burn and scald and makes the wound surface convergence granulation promoting.Zinc sulfate belongs to chemical drugs, is the indispensable trace element of human body, and zinc can be kept epithelial normal reparation, fibroblast proliferation, epithelium formation, collagen is synthesized play an important role.Other Chinese medicine ingredients contains tannin, volatile oil, aminoacid, organic acid, various vitamin, flavonoid glycoside etc.The present invention forms science, mainly acts on removing heat from blood, hemostasis, convergence, pain relieving, granulation promoting, sterilization, infection, inhibition cicatrization.This medicine should be given birth to usefulness, is medicine for external use, and preparation method is simple, and each component is mixed, pulverized, and sieving gets final product.
Curative effect of the present invention is reliable, has no side effect, to treating all kinds of burn and scald effective percentage 100%, cure rate 100%.The present invention also has very strong epilepsy therapeutical effect.Consumption is few, and effect is fast, clinically is used for the treatment of all kinds of burn and scald, and 60% area infects two degree burn and scald with interior nothing, and topical agent is once cured preventing from scar in 15～20 days after conventional infection, supporting treatment, the debridement.30% area, need not made skin graft through several or tens topical agents with three interior degree burn and scald.To this, treat early preventing from scar; If infect, treat untimelyly, can stay cicatrix to some extent.10～12 hours dryings behind the topical agent of the present invention form an airtight protective layer, stop body fluid to ooze out, and prevent outside antibacterial intrusion.All kinds of burn and scald 1216 examples of clinical treatment, existing 168 routine patients are wherein done following clinical report:
One, case is selected:
1,1～16 years old 67 example among the 168 routine patients, 17～67 years old 101 example; Male's 126 examples, women's 42 examples.
2, sulphuric acid, alkaline burn, Colophonium 17 examples of burning; Gasoline, liquefied gas 38 examples of burning; Electric injury 1 example; Boiling property liquid is scalded 112 examples.Wherein women's head-ornaments portion, cervical region, hands, trunk, breast, foot burn and scald 69 examples, 99 examples are extremity position wound.
3, burn and scald area minimum 1%, maximum 55%.
4, the burn and scald degree of depth: two degree 1%～55% area 142 examples, two degree burn and scald infect to 3-degree wound and three degree burn and scald 1%～30% with inner area 26 examples.
5, burn and scald classification: slight 86 examples, moderate 44 examples, severe 15 examples, extra heavy 3 examples.
6, consultation time: 87 examples in 12 hours, 59 examples in 24～72 hours, 22 examples in 4 days～30 days.
Two, diagnostic criteria:
1, by the caused damage of heating power (flame, scorching hot, gas, liquid or solid etc.).
2, the burn and scald area is estimated: Chinese rule of Nine
3, burn and scald estimation of Depth: three degree quarterings
4, burn and scald degree classification: the criteria for classification that whole nation burn meeting in 1970 is drafted
(1) slight burn and scald: the gross area is at the degree of two below 9% burn and scald;
(2) moderate burn and scald: the gross area is between 10%～29%, or three degree burn and scald areas are below 10%;
(3) severe burn and scald: the gross area is between 30%～49%, or three degree burn and scald area between 10%～19% or burn and scald area less than 30%, but one of following situation person is arranged: (1) whole body situation is heavier or suffered a shock, and (2) combined injury is in (3), moderate and severe inhalation;
(4) extra heavy burn and scald: the gross area is more than 50%, or three degree burn and scald areas are more than 20%.
Three, clinical treatment:
Therapeutic Method: conventional debridement, infection, supporting treatment: after the debridement powder medicine for treating born and scald of the present invention is sprinkling upon on the wound surface equably, thick about 0.3～0.5 millimeter exposes wound surface.
Four, efficacy evaluation:
1, FFI topical agent below 60% is cured preventing from scar in one time 15～20 days.
2,10% with three interior degree burn and scald, and wound surface does not have infection, and medication need not made skin graft preventing from scar for several times.
3, two degree burn and scald with the treatment of other method surpass the disunion of first quarter moon wound surface or and infect, small size three degree burn and scald treatments surpass first quarter moon, use the present invention's treatment instead, after healing in various degree leave cicatrix.
4, Drug therapy of the present invention is promptly used at face, hands, function of joint position after the wound, more the no cicatrix in back.Function is unaffected.
5, except strong acid, the highly basic burn and scald
6, except the severe muscle burn and scald.
Five: characteristics
1, FFI two degree empyrosis wound surface medications are once cured, and do not need the stimulation wound surface of changing dressings every day.
2,30% with three interior degree empyrosis wound surface medications, and medication according to circumstances is for several times to tens of healings.
3,10～12 hours dryings behind the topical agent form an airtight protective layer, stop body fluid to ooze out, and prevent outside antibacterial intrusion.
4, aseptic condition is not strict, alleviates medical personnel's workload.
5, routine blood test, biochemical analysis is no abnormal.
6, in above-mentioned 42 routine female patients, there are 2 examples to burn because of epilepsy grand mal.An example burn head wherein, an example burn breast, abdomen, lower limb.The patient of head burn, after burn was cured, epileptics was also cured, not recurrence in 9 years so far.Another routine patient, after burn was cured, epilepsy was cured substantially, and under insensibility stimulated, oneself can the controlling symptoms outbreak.
Six, case introduction
Example one: the week * *, man 32 years old, the gas that is liquefied burn, women's head-ornaments, neck, breast, abdomen, extremity portion, both hands, the second degree burn area is about 55%, and conventional anti-infective therapy adds supporting treatment, and the external powder medicine for treating born and scald was cured preventing from scar in one time 15 days.
Example two: the king * *, the woman, 26 years old, by the two lower limb of petrol burn, hinder the back and treat 30 days to severe infections at private clinic's secret recipe, when coming my institute, 41 ℃ of T, BP12/8Kpa, P120 time/minute, HD6 gram, WBC14.6 * 10
9/ I.Staring spells, bradykinesia, electrolyte disturbance, septicemia, tetanus symptom typical case.Wound surface is wrapped up with toilet paper, covers pus, skin injury about 25%.First visit: 1, burn and severe infections, skin injury 25%; 2, hemorrhagic anemia (miscarriage is lost blood before the burn); 3, septicemia; 4, tetanus; 5, electrolyte is seriously disorderly.Handle, debridement, infection is corrected anemia, tetanus treatment, supporting treatment.Wound surface external powder medicine for treating born and scald exposure method, hospitalization 199 days, not skin-grafting.The outside, lacquer joint, right side, mild scar, contracture, the activity of row lysis posterior joint is as usual, good springiness after other wound surface skin repair, cicatrix is not obvious.
Seven, contrast:
Contrast with the moist expose burn ointment that generally uses clinically at present: moist expose burn ointment is pretty good to the FFI wound surface curative effect of the second degree burn below 5%, and is undesirable with the wound surface effect that infects more than 10%.
With the second degree burn wound surface is benchmark, and medicine medication of the present invention was once cured in 10～15 days.The moist expose burn ointment twice-daily is coated with wound surface disunion in 15～20 days.The inventor has just accepted the 22 routine second degree burn wounded for medical treatment, uses powder medicine for treating born and scald of the present invention instead and cure after the moist expose burn ointment treatment needed skin-grafting more than 20 days, need not make skin graft.The present invention and moist expose burn ointment are used for same routine second degree burn patient, the right hand, forearm with the present invention once, wound surface exposes, and cures in 15 days.Left side forearm is coated with 0.5 cm thick outward with moist expose burn ointment, and sterile gauze wrapping day is changed dressings once, in the time of 15 days traumatic infection to 3-degree wound, after use the present invention instead and treated cicatrization 20 days." the medical officer people " 1996.4 (61), 151 Li Zhi armies of hospital of PLA etc. have reported that " moist expose burn ointment causes the right hand and infects 1 example " confirmed deep burn is failed to respond to any medical treatment, to the superficial burns easy infection.
Eight, demonstration
Powder medicine for treating born and scald has effects such as convergence, granulation promoting, coagulated protein, sterilization, infection.Be used for the burn and scald patient and make wound surface form airtight protective layer, control infection suppresses the bacillus pyocyaneus growth, prevents that septicemia from taking place.Powder medicine for treating born and scald can activate epithelial cell, promotes normal structure to form, and helps the wound surface immediate union.This medicine can be kept epithelial normal reparation, fibroblastic regeneration, epithelium formation, collagen is synthesized play an important role.Because pharmaceutical formulation is reasonable, some medicine can suppress cicatrix, so fibroblastic transition propagation and chaotic keloid propagation are had inhibition and mitigation.
This medicine is spent large-area burns and 30% with interior third degree burn effective percentage 100%, cure rate 100% through clinical verification to two below 60%.
Embodiment one: most preferred embodiment
5 parts of egg membranes, side uncle leaf 10, Folium Mori 10, the Radix Angelicae Dahuricae 10, Olibanum 10, Myrrha 10, Radix Sanguisorbae 10, Folium Ilicis Purpureae 10, Aloe 10, Borneolum Syntheticum 5, zinc sulfate 0.25
Embodiment two:
3 parts of egg membranes, side uncle leaf 8, Folium Mori 6, the Radix Angelicae Dahuricae 5, Olibanum 7, Myrrha 5, Radix Sanguisorbae 8, Folium Ilicis Purpureae 10, Aloe 6, Borneolum Syntheticum 3, zinc sulfate 0.3
Embodiment three:
1 part of egg membrane, side uncle leaf 5, Folium Mori 5, the Radix Angelicae Dahuricae 8, Olibanum 9, Myrrha 7, Radix Sanguisorbae 5, Folium Ilicis Purpureae 7, Aloe 5, Borneolum Syntheticum 1, zinc sulfate 0.25
Embodiment four:
4 parts of egg membranes, side uncle leaf 10, Folium Mori 8, the Radix Angelicae Dahuricae 6, Olibanum 5, Myrrha 5, Radix Sanguisorbae 7, Folium Ilicis Purpureae 5, Aloe 8, Borneolum Syntheticum 4, zinc sulfate 0.3
Embodiment five:
5 parts of egg membranes, side uncle leaf 5, Folium Mori 5, the Radix Angelicae Dahuricae 8, Olibanum 9, Myrrha 10, Radix Sanguisorbae 10, Folium Ilicis Purpureae 6, Aloe 10, Borneolum Syntheticum 1, zinc sulfate 0.25, catechu 6, Herba Centellae 10
Embodiment six:
1 part of egg membrane, side uncle leaf 8, Folium Mori 10, the Radix Angelicae Dahuricae 5, Olibanum 6, Myrrha 5, Radix Sanguisorbae 7, Folium Ilicis Purpureae 5, Aloe 8, Borneolum Syntheticum 2, zinc sulfate 0.3, catechu 8, Herba Centellae 5, Mirabilitum crystallina 6
Claims (3)
1, a kind of powder medicine for treating born and scald is characterized in that it being that raw material by by following parts by weight is made:
1～5 part of egg membrane, side uncle leaf 5～10, Folium Mori 5～10, the Radix Angelicae Dahuricae 5～10, Olibanum 5～10, Myrrha 5～10, Radix Sanguisorbae 5～10, Folium Ilicis Purpureae 5～10, Aloe 5～10, Borneolum Syntheticum 1～5, zinc sulfate 0.25～0.3.
2, powder medicine for treating born and scald according to claim 1 is characterized in that also comprising raw material: in catechu 5～10, Herba Centellae 5～10, the Mirabilitum crystallina 5～10 1～3 kind.
3, powder medicine for treating born and scald according to claim 1 is characterized in that being made by 5 parts of egg membranes, side uncle leaf 10, Folium Mori 10, the Radix Angelicae Dahuricae 10, Olibanum 10, Myrrha 10, Radix Sanguisorbae 10, Folium Ilicis Purpureae 10, Aloe 10, Borneolum Syntheticum 5, zinc sulfate 0.25.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99112563A CN1079257C (en) | 1999-11-16 | 1999-11-16 | Powder medicine for treating born and scald |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99112563A CN1079257C (en) | 1999-11-16 | 1999-11-16 | Powder medicine for treating born and scald |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1295848A CN1295848A (en) | 2001-05-23 |
| CN1079257C true CN1079257C (en) | 2002-02-20 |
Family
ID=5275857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99112563A Expired - Fee Related CN1079257C (en) | 1999-11-16 | 1999-11-16 | Powder medicine for treating born and scald |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1079257C (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102018742B (en) * | 2010-11-17 | 2012-05-16 | 盘吉荣 | External traditional Chinese medicine for treating burns and scalds and preparation method thereof |
| CN102423377A (en) * | 2011-12-07 | 2012-04-25 | 梁凤姣 | External ointment for treating burns and scalds and preparation method thereof |
| PL3212204T3 (en) | 2014-10-28 | 2019-11-29 | Biovotec As | Micronized eggshell membrane particles and the use thereof to promote the healing of wounds |
| US11045578B2 (en) | 2015-06-24 | 2021-06-29 | Biovotec As | Tissue engineering scaffolds comprising particulate egg shell membrane |
| GB201519923D0 (en) | 2015-11-11 | 2015-12-23 | Biovotec Dac And Biovotec As | Dry biocompatible disintegrateable films for delivering particulate egg shell membrane to a wound |
| CN107007761B (en) * | 2017-06-05 | 2020-01-31 | 唐永奎 | A Chinese medicinal oil for treating burn, and its preparation method |
| CN108635521A (en) * | 2018-06-29 | 2018-10-12 | 李士洋 | A kind of topical composition and preparation method thereof for treating burn and scald |
-
1999
- 1999-11-16 CN CN99112563A patent/CN1079257C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1295848A (en) | 2001-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101534468B1 (en) | Use of Pharmaceutical Compositions in Preparing Pharmaceuticals for Treating Diabetic Ulcer | |
| CN108853312B (en) | Polycinnamic alcohol external gel and preparation method thereof | |
| CN101569696A (en) | Chinese medicament for traumatic wound | |
| CN1079257C (en) | Powder medicine for treating born and scald | |
| CN103566071B (en) | Traditional Chinese medicine composition for treating ulcer and preparation method of powder of traditional Chinese medicine composition | |
| CN112618646A (en) | Traditional Chinese medicine composition and traditional Chinese medicine oil for treating burns and preparation method thereof | |
| CN101703651A (en) | Medicament for treating diabetic gangrene | |
| CN1471938A (en) | Medicine for treating superficial and deep burn and scald | |
| CN1183950C (en) | Chinese herbal medicine preparation for treating burns | |
| CN1259098C (en) | Exterior-applied Chinese herbal medicine preparation for traumatic infection and inflammation-relieving acesodyne and its preparation method | |
| CN1261117C (en) | Medicine for treating bum, empyrosis and bedsore | |
| CN1259052C (en) | Medicinal composition for treating burn and scald and preparing method | |
| CN1172700C (en) | External applied medicine for curing burn and preparing method thereof | |
| CN1068785C (en) | Chinese patent medicine for external application for curing diseases of scald, burn and dermal ulcer | |
| CN1258367C (en) | Medicine for treating trauma | |
| CN1072499C (en) | External-use medicine for curing various chronic ulcers | |
| CN100388921C (en) | A drug that makes wounds heal faster | |
| CN101647952A (en) | Flesh engendering and wound closing medicament for external use | |
| CN1067879C (en) | Preparation of medicament containing rare-earth for dermatomycosis | |
| CN100370998C (en) | Chinese medicinal preparation for treating sore, and wound and turn and scald | |
| CN112353922A (en) | Traditional Chinese medicine composition and application and preparation method thereof | |
| CN1236798C (en) | External medicine for treating bone tuberculosis | |
| CN111939181A (en) | Medicinal powder for treating burns and scalds | |
| CN1772077A (en) | Medicine liquid for treating burns and scalds and its prepn | |
| US12115186B1 (en) | Topical burn cream |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |